



Request for Prior Authorization
HEPATITIS C TREATMENTS

(PLEASE PRINT – ACCURACY IS IMPORTANT)

Form with fields for IA Medicaid Member ID #, Patient name, DOB, Patient address, Patient phone, Provider NPI, Prescriber name, Phone, Prescriber address, Fax, Pharmacy name, Address, Phone, Pharmacy NPI, Pharmacy fax, NDC.

Prior authorization (PA) is required for hepatitis C treatments. Requests for non-preferred agents may be considered when documented evidence is provided that the use of the preferred agents would be medically contraindicated. Payment will be considered under the following conditions: 1) Patient has a diagnosis of chronic hepatitis C; and 2) Patient's age and/or weight is within the FDA labeled age and/or weight; and 3) Patient has had testing for hepatitis C virus (HCV) genotype; and 4) Patient has an active HCV infection verified by a detectable viral load within 12 months of starting treatment; and 5) Patient has been tested for hepatitis B (HBV) prior to initiating treatment of HCV and individuals with active HBV infection are treated (either at same time as HCV therapy or before HCV therapy is started); and 6) Patient has advanced liver disease corresponding to a Metavir score of 2 or greater fibrosis as confirmed by one of the following: a) liver biopsy confirming a Metavir score ≥2; or b) transient elastography (FibroScan) score ≥ 7.5kPa; or c) FibroSURE (FibroTest) score ≥0.48; or d) APRI score >0.7; or e) radiological imaging consistent with cirrhosis (i.e., evidence of portal hypertension); or f) physical findings or clinical evidence consistent with cirrhosis; or g) patients at highest risk for severe complications: organ transplant, type 2 or 3 essential mixed cryoglobulinemia with end-organ manifestations (e.g. vasculitis), proteinuria, nephrotic syndrome, or membranoproliferative glomerulonephritis; and 7) Patient's prior treatment history is provided (treatment naïve or treatment experienced); and 8) If patient has a history of non-compliance, documentation that steps have been taken to correct or address the causes of non-compliance are provided; and 9) Patient has abstained from the use of illicit drugs and alcohol for a minimum of three (3) months as evidenced by a negative urine confirmation test; and 10) For regimens containing sofosbuvir (Sovaldi/ledipasvir/sofosbuvir/sofosbuvir/velpatasvir/Vosevi), patient does not have severe renal impairment (creatinine clearance <30ml/min) or end stage renal disease requiring hemodialysis; and 11) HCV treatment is prescribed by or in consultation with a digestive disease, liver disease, or infectious disease provider practice; and 12) For patients on a regimen containing ribavirin, documentation of the following on the PA form: a) Patient is not a pregnant female or a male with a pregnant female partner; and b) Women of childbearing potential and their male partners must use two forms of effective contraception during treatment and for at least 6 months after treatment has concluded; and c) Monthly pregnancy tests will be performed during treatment; and 13) Prescriber has reviewed the patient's current medication list and acknowledged that there are no significant drug interactions with the HCV medication; and 14) Documentation is provided for patients who are ineligible to receive ribavirin. 15) Non-FDA approved or non-compensated combination therapy regimens will not be approved. 16) Patient does not have limited life expectancy (less than 12 months) due to non-liver-related comorbid conditions. 17) If patient is recently eligible for Iowa Medicaid, and has been started and stabilized on therapy while covered under a different plan, documentation of how long the patient has been on medication will be required. Patient will be eligible for the remainder of therapy needed, based on established length of therapy for the particular treatment (defined below). 18) Lost or stolen medication replacement requests will not be authorized. 19) The 72-hour emergency supply rule does not apply to hepatitis C treatments. 20) Only one treatment attempt will be allowed per calendar year, regardless of compliance.

- Preferred: [ ] Mavyret, [ ] Sofosbuvir/Velpatasvir
Non-Preferred: [ ] Daklinza, [ ] Epclusa, [ ] Harvoni, [ ] Ledipasvir/Sofosbuvir, [ ] Sovaldi, [ ] Vosevi, [ ] Zepatier

Instructions for completing the Hepatitis C Treatments PA form:

Section 1 of the PA form lists the various regimens and clinical situations for which hepatitis C treatments will be considered medically necessary according to Iowa Medicaid PA criteria. Section 2 includes additional supporting documentation that is required on the PA form.

- Check ONE box in Section 1 – Treatment Regimen.

Iowa Department of Human Services  
**Request for Prior Authorization**  
**HEPATITIS C TREATMENTS**  
(PLEASE PRINT – ACCURACY IS IMPORTANT)

- Review and complete each numbered item in Section 2 – Supporting Documentation.
- Attach lab results, chart notes, and other documentation, sign, and fax the completed form to (800) 574-2515.

**SECTION 1 – TREATMENT REGIMEN**

Check **ONE** box below to indicate the requested treatment regimen based on the patient’s genotype, treatment history, and extent of liver disease.

<b>Genotype 1 (Note: the subtype is listed if there are differences in the recommended treatments)</b>
<b>Treatment naïve, no cirrhosis</b> <input type="checkbox"/> Mavyret 100/40 mg, three (3) tablets daily for 8 weeks <input type="checkbox"/> sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks
<b>Treatment naïve, compensated cirrhosis (Child-Pugh A ONLY)</b> <input type="checkbox"/> Mavyret 100/40 mg, three (3) tablets daily for 12 weeks <input type="checkbox"/> sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks
<b>Treatment experienced (PEG-IFN/RBV ONLY), no cirrhosis</b> <input type="checkbox"/> Mavyret 100/40 mg, three (3) tablets daily for 8 weeks <input type="checkbox"/> sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks
<b>Treatment experienced (PEG-IFN/RBV ONLY), compensated cirrhosis (Child-Pugh A ONLY)</b> <input type="checkbox"/> Mavyret 100/40 mg, three (3) tablets daily for 12 weeks <input type="checkbox"/> sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks
<b>Treatment experienced (PEG-IFN/RBV + NS3/4A protease inhibitor, no prior NS5A, no prior sofosbuvir), no cirrhosis</b> <input type="checkbox"/> Mavyret 100/40 mg, three (3) tablets daily for 12 weeks <input type="checkbox"/> sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks
<b>Treatment experienced (PEG-IFN/RBV+NS3/4A protease inhibitor, no prior NS5A, no prior sofosbuvir), compensated cirrhosis (Child-Pugh A ONLY)</b> <input type="checkbox"/> Mavyret 100/40 mg, three (3) tablets daily for 12 weeks <input type="checkbox"/> sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks
<b>Treatment experienced (sofosbuvir + ribavirin +/- PEG-IFN OR simeprevir, no NS5A), no cirrhosis</b> <input type="checkbox"/> Mavyret 100/40 mg, three (3) tablets daily for 12 weeks <input type="checkbox"/> 1b: sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks
<b>Treatment experienced (sofosbuvir + ribavirin +/- PEG-IFN OR simeprevir, no NS5A), compensated cirrhosis (Child-Pugh A ONLY)</b> <input type="checkbox"/> Mavyret 100/40 mg, three (3) tablets daily for 12 weeks <input type="checkbox"/> 1b: sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks
<b>Treatment experienced, any NS5A inhibitor but NO NS3/4A protease inhibitor (prior therapy ONLY with daclatasvir+sofosbuvir, ledipasvir+sofosbuvir or sofosbuvir +velpatasvir), no or compensated cirrhosis (Child-Pugh A ONLY)</b> <input type="checkbox"/> Mavyret 100/40 mg, three (3) tablets daily for 16 weeks <input type="checkbox"/> Vosevi 400/100/100 mg daily for 12 weeks
<b>Treatment experienced (prior treatment with any NS5A inhibitor (ledipasvir (Harvoni), velpatasvir (Epclusa/Vosevi), elbasvir (Zepatier), dasabuvir (Viekira), pibrentasvir (Mavyret) and daclatasvir (Daklinza), including those given with a NS3/4A protease inhibitor), no cirrhosis or compensated cirrhosis (Child-Pugh A ONLY)</b> <input type="checkbox"/> Vosevi 400/100/100 mg daily for 12 weeks
<b>Re-infection of allograft liver after transplant, no cirrhosis</b> <input type="checkbox"/> Mavyret 100/40 mg, three (3) tablets daily for 12 weeks
<b>Re-infection of allograft liver after transplant, compensated cirrhosis (Child-Pugh A ONLY)</b> <input type="checkbox"/> ledipasvir/sofosbuvir 90/400 mg plus weight based ribavirin daily for 12 weeks
<b>Re-infection of allograft liver after transplant, decompensated cirrhosis (Child-Pugh B or C ONLY)</b> <input type="checkbox"/> ledipasvir/sofosbuvir 90/400 mg plus low dose ribavirin <sup>#</sup> daily for 12 weeks
<b>Decompensated cirrhosis, no prior sofosbuvir or NS5A</b> <input type="checkbox"/> sofosbuvir/velpatasvir 400/100 mg plus weight-based ribavirin daily for 12 weeks (low dose ribavirin <sup>#</sup> if Child-Pugh Class C) <input type="checkbox"/> sofosbuvir/velpatasvir 400/100 mg daily for 24 weeks (will be approved only for patients with documented ineligibility for ribavirin <sup>†</sup> )

Iowa Department of Human Services  
**Request for Prior Authorization**  
**HEPATITIS C TREATMENTS**  
(PLEASE PRINT – ACCURACY IS IMPORTANT)

<b>Decompensated cirrhosis, prior treatment with sofosbuvir or NS5A</b> <input type="checkbox"/> sofosbuvir/velpatasvir 400/100 mg plus weight-based ribavirin daily for 24 weeks (low dose ribavirin if Child-Pugh Class C)
<b>Recurrent HCV infection post–liver transplantation, no cirrhosis</b> <input type="checkbox"/> Mavyret 100/40 mg, three (3) tablets daily for 12 weeks
<b>Recurrent HCV infection post–liver transplantation, compensated cirrhosis (Child-Pugh A ONLY)</b> <input type="checkbox"/> ledipasvir/sofosbuvir 90/400 mg plus weight based ribavirin daily for 12 weeks
<b>Recurrent HCV infection post–liver transplantation, decompensated cirrhosis (Child-Pugh B and C ONLY)</b> <input type="checkbox"/> ledipasvir/sofosbuvir 90/400 mg plus low dose ribavirin <sup>#</sup> daily for 12 weeks
<b>Genotype 2</b>
<b>Treatment naïve, no cirrhosis</b> <input type="checkbox"/> Mavyret 100/40 mg, three (3) tablets daily for 8 weeks <input type="checkbox"/> sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks
<b>Treatment naïve, compensated cirrhosis (Child-Pugh A ONLY)</b> <input type="checkbox"/> Mavyret 100/40 mg, three (3) tablets daily for 12 weeks <input type="checkbox"/> sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks
<b>Treatment experienced (PEG-IFN + ribavirin), no cirrhosis</b> <input type="checkbox"/> Mavyret 100/40 mg, three (3) tablets daily for 8 weeks <input type="checkbox"/> sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks
<b>Treatment experienced (PEG-IFN + ribavirin), with compensated cirrhosis (Child-Pugh A only)</b> <input type="checkbox"/> Mavyret 100/40 mg, three (3) tablets daily for 12 weeks <input type="checkbox"/> sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks
<b>Treatment experienced (sofosbuvir + ribavirin) (no cirrhosis)</b> <input type="checkbox"/> Mavyret 100/40 mg, three (3) tablets daily for 8 weeks (label indication) or 12 (guideline recommendation) weeks <input type="checkbox"/> sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks
<b>Treatment experienced (sofosbuvir + ribavirin) with compensated cirrhosis (Child-Pugh A only)</b> <input type="checkbox"/> Mavyret 100/40 mg, three (3) tablets daily for 12 weeks <input type="checkbox"/> sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks
<b>Treatment experienced, (sofosbuvir + any NS5A inhibitor) with or without compensated cirrhosis (Child-Pugh A only)</b> <input type="checkbox"/> Vosevi 400/100/100 mg daily for 12 weeks
<b>Decompensated cirrhosis, no prior sofosbuvir or NS5A failure</b> <input type="checkbox"/> sofosbuvir/velpatasvir 400/100 mg plus weight-based ribavirin daily for 12 weeks <input type="checkbox"/> sofosbuvir/velpatasvir 400/100 mg daily for 24 weeks (will be approved only for patients with documented ineligibility for ribavirin <sup>(f)</sup> )
<b>Decompensated cirrhosis, prior sofosbuvir or NS5A failure</b> <input type="checkbox"/> sofosbuvir/velpatasvir 400/100 mg plus weight based ribavirin daily for 24 weeks (low dose ribavirin if Child-Pugh C)
<b>Recurrent HCV infection post–liver transplantation, no cirrhosis</b> <input type="checkbox"/> Mavyret 100/40 mg, three (3) tablets daily for 12 weeks
<b>Recurrent HCV infection post–liver transplantation, compensated cirrhosis (Child-Pugh A ONLY)</b> <input type="checkbox"/> sofosbuvir/velpatasvir 400/100 mg plus weight-based ribavirin daily for 12 weeks <input type="checkbox"/> Mavyret 100/40 mg, three (3) tablets daily for 12 weeks
<b>Recurrent HCV infection post–liver transplantation, decompensated cirrhosis</b> <input type="checkbox"/> sofosbuvir/velpatasvir 400/100 mg plus weight-based ribavirin daily for 12 weeks
<b>Genotype 3</b>
<b>Treatment naïve, no cirrhosis</b> <input type="checkbox"/> Mavyret 100/40 mg, three (3) tablets daily for 8 weeks <input type="checkbox"/> sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks
<b>Treatment naïve, with compensated cirrhosis (Child-Pugh A only), Y93H negative</b> <input type="checkbox"/> Mavyret 100/40 mg, three (3) tablets daily for 12 weeks (Child-Pugh A only) <input type="checkbox"/> sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks

Iowa Department of Human Services  
**Request for Prior Authorization**  
**HEPATITIS C TREATMENTS**  
(PLEASE PRINT – ACCURACY IS IMPORTANT)

<b>Treatment naïve, with compensated cirrhosis (Child-Pugh A only), Y93H positive</b> <input type="checkbox"/> Mavyret 100/40 mg, three (3) tablets daily for 12 weeks <input type="checkbox"/> sofosbuvir/velpatasvir 400/100 mg plus weight-based ribavirin daily for 12 weeks
<b>Treatment experienced (PEG-IFN + ribavirin), no cirrhosis, Y93H negative</b> <input type="checkbox"/> sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks <input type="checkbox"/> Mavyret 100/40 mg, three (3) tablets daily for 16 weeks
<b>Treatment experienced (PEG-IFN + ribavirin), no cirrhosis, Y93H positive</b> <input type="checkbox"/> sofosbuvir/velpatasvir 400/100 mg plus weight-based ribavirin daily for 12 weeks <input type="checkbox"/> Mavyret 100/40 mg, three (3) tablets daily for 16 weeks
<b>Treatment experienced (PEG-IFN + ribavirin), compensated cirrhosis (Child-Pugh A ONLY)</b> <input type="checkbox"/> Mavyret 100/40 mg, three (3) tablets daily for 16 weeks <input type="checkbox"/> sofosbuvir/velpatasvir 400/100 mg plus weight-based ribavirin daily for 12 weeks
<b>Treatment experienced (any direct acting antiviral including NS5A), no or compensated cirrhosis (Child-Pugh A ONLY)</b> <input type="checkbox"/> Vosevi 400/100/100 mg daily for 12 weeks (add weight based ribavirin if both prior NS5A and cirrhosis)
<b>Decompensated cirrhosis, no prior sofosbuvir or NS5A failure</b> <input type="checkbox"/> sofosbuvir/velpatasvir 400/100 mg plus weight-based ribavirin daily for 12 weeks <input type="checkbox"/> sofosbuvir/velpatasvir 400/100 mg daily for 24 weeks (will only be approved for patients with documented ineligibility for ribavirin <sup>[1]</sup> )
<b>Decompensated cirrhosis, prior sofosbuvir or NS5A failure</b> <input type="checkbox"/> sofosbuvir/velpatasvir 400/100 mg plus weight-based ribavirin daily for 24 weeks (low dose ribavirin <sup>#</sup> if Child-Pugh C)
<b>Recurrent HCV infection post–liver transplantation, no cirrhosis</b> <input type="checkbox"/> Mavyret 100/40 mg, three (3) tablets daily for 12 weeks
<b>Recurrent HCV infection post–liver transplantation, compensated cirrhosis (Child-Pugh A ONLY)</b> <input type="checkbox"/> sofosbuvir/velpatasvir 400/100 mg plus weight-based ribavirin daily for 12 weeks <input type="checkbox"/> Mavyret 100/40 mg, three (3) tablets daily for 12 weeks
<b>Recurrent HCV infection post–liver transplantation, decompensated cirrhosis (Child-Pugh B and C ONLY)</b> <input type="checkbox"/> sofosbuvir/velpatasvir 400/100 mg plus weight-based ribavirin daily for 12 weeks
<b>Genotype 4</b>
<b>Treatment naïve, no cirrhosis</b> <input type="checkbox"/> Mavyret 100/40 mg, three (3) tablets daily for 8 weeks <input type="checkbox"/> sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks
<b>Treatment naïve, compensated cirrhosis (Child-Pugh A only)</b> <input type="checkbox"/> Mavyret 100/40 mg, three (3) tablets daily for 12 weeks <input type="checkbox"/> sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks
<b>Treatment experienced (PEG-IFN/RBV ONLY), no cirrhosis</b> <input type="checkbox"/> Mavyret 100/40 mg, three (3) tablets daily for 8 weeks <input type="checkbox"/> sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks
<b>Treatment experienced (PEG-IFN/RBV ONLY), compensated cirrhosis (Child-Pugh A only)</b> <input type="checkbox"/> Mavyret 100/40 mg, three (3) tablets daily for 12 weeks <input type="checkbox"/> sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks
<b>Treatment experienced (any direct acting antiviral including NS5A), with or without compensated cirrhosis (Child-Pugh A ONLY)</b> <input type="checkbox"/> Vosevi 400/100/100 mg daily for 12 weeks
<b>Decompensated cirrhosis, no prior sofosbuvir or NS5A</b> <input type="checkbox"/> sofosbuvir/velpatasvir 400/100 mg plus weight-based ribavirin daily for 12 weeks (low dose ribavirin <sup>#</sup> if Child-Pugh C) <input type="checkbox"/> sofosbuvir/velpatasvir 400/100 mg daily for 24 weeks (will only be approved for patients with documented ineligibility for ribavirin <sup>[1]</sup> )
<b>Decompensated cirrhosis, prior treatment with sofosbuvir or NS5A</b> <input type="checkbox"/> sofosbuvir/velpatasvir 400/100 mg plus weight-based ribavirin daily for 24 weeks (low dose ribavirin <sup>#</sup> if Child-Pugh C)
<b>Recurrent HCV infection post–liver transplantation, no cirrhosis</b> <input type="checkbox"/> Mavyret 100/40 mg, three (3) tablets daily for 12 weeks
<b>Recurrent HCV infection post–liver transplantation, compensated cirrhosis (Child-Pugh A ONLY)</b> <input type="checkbox"/> ledipasvir/sofosbuvir 90/400 mg plus weight-based ribavirin daily for 12 weeks

Iowa Department of Human Services  
**Request for Prior Authorization**  
**HEPATITIS C TREATMENTS**  
(PLEASE PRINT – ACCURACY IS IMPORTANT)

<b>Recurrent HCV infection post–liver transplantation, decompensated cirrhosis</b> <input type="checkbox"/> ledipasvir/sofosbuvir 90/400 mg plus low dose ribavirin# daily for 12 weeks
<b>Genotype 5 or 6</b>
<b>Treatment naïve, no cirrhosis</b> <input type="checkbox"/> Mavyret 100/40 mg, three (3) tablets daily for 8 weeks <input type="checkbox"/> sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks
<b>Treatment naïve, compensated cirrhosis (Child-Pugh A only)</b> <input type="checkbox"/> Mavyret 100/40 mg, three (3) tablets daily for 12 weeks <input type="checkbox"/> sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks
<b>Treatment experienced (PEG-IFN/RBV), no cirrhosis</b> <input type="checkbox"/> Mavyret 100/40 mg, three (3) tablets daily for 8 weeks <input type="checkbox"/> sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks
<b>Treatment experienced (PEG-IFN/RBV), compensated cirrhosis (Child-Pugh A ONLY)</b> <input type="checkbox"/> Mavyret 100/40 mg, three (3) tablets daily for 12 weeks <input type="checkbox"/> sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks
<b>Treatment experienced (any Direct Acting HCV Antiviral (DAA) including NS5A inhibitors, with no or compensated cirrhosis (Child-Pugh A ONLY)</b> <input type="checkbox"/> Vosevi 400/100/100 mg daily for 12 weeks
<b>Decompensated cirrhosis, no prior sofosbuvir or NS5A</b> <input type="checkbox"/> sofosbuvir/velpatasvir 400/100 mg plus weight-based ribavirin daily for 12 weeks (low dose ribavirin# if Child-Pugh C) <input type="checkbox"/> sofosbuvir/velpatasvir 400/100 mg daily for 24 weeks (will only be approved for patients with documented ineligibility to ribavirin <sup>(f)</sup> )
<b>Decompensated cirrhosis, prior treatment with sofosbuvir or NS5A</b> <input type="checkbox"/> sofosbuvir/velpatasvir 400/100 mg plus weight-based ribavirin daily for 24 weeks (low dose ribavirin# if Child-Pugh C)
<b>Recurrent HCV infection post–liver transplantation, no cirrhosis</b> <input type="checkbox"/> Mavyret 100/40 mg, three (3) tablets daily for 12 weeks
<b>Recurrent HCV infection post–liver transplantation, compensated cirrhosis (Child-Pugh A ONLY)</b> <input type="checkbox"/> ledipasvir/sofosbuvir 90/400 mg plus weight-based ribavirin daily for 12 weeks
<b>Recurrent HCV infection post–liver transplantation, decompensated cirrhosis</b> <input type="checkbox"/> ledipasvir/sofosbuvir 90/400 mg plus low dose ribavirin# daily for 12 weeks
<b>Other Treatment Regimen</b>
Genotype, treatment history, and extent of liver disease: _____ Drug name, dose and duration: _____ Clinical rationale for selecting regimens other than those outlined above: _____ _____ _____

Abbreviations: PEG-IFN=peg-interferon; RBV=ribavirin; PI=protease inhibitor; DAA=direct acting antiviral

# low dose ribavirin = 600 mg/day and increase as tolerated

^Dose of Daklinza (daclatasvir) MUST BE ADJUSTED with certain co-administered drugs (reduced to 30 mg daily with concurrent CYP3A4 inhibitors and increased to 90 mg daily with concurrent moderate CYP3A4 inducers)

Iowa Department of Human Services  
**Request for Prior Authorization**  
**HEPATITIS C TREATMENTS**  
(PLEASE PRINT – ACCURACY IS IMPORTANT)

**SECTION 2 – SUPPORTING DOCUMENTATION**

Review and complete each numbered item below to provide the supporting documentation for the PA request.

**Diagnosis:**

1. Pretreatment viral load (**attach results**): \_\_\_\_\_ Date Obtained: \_\_\_\_\_
2. Documentation of advanced liver disease (**attach results**): \_\_\_\_\_ Date Obtained: \_\_\_\_\_
- Liver biopsy confirming a Metavir score  $\geq$  F2
  - Transient elastography (FibroScan) score  $\geq$  7.5kPa
  - FibroSURE (FibroTest) score  $\geq$  0.48
  - APRI score  $>$  0.7
  - Radiological imaging consistent with cirrhosis (i.e. evidence of portal hypertension)
  - Physical findings or clinical evidence consistent with cirrhosis
  - Patients at highest risk for severe complications: organ transplant, type 2 or 3 essential mixed cryoglobulinemia with end-organ manifestations (e.g. vasculitis), proteinuria, nephrotic syndrome, or membranoproliferative glomerulonephritis.

**Patient History:**

3. Does the patient have a history of non-compliance?  Yes  No  
If yes, submit chart notes documenting the steps taken to correct or address the non-compliance (**attach chart notes**)
4. Documentation in provider notes (**must be submitted**) showing that member has had no abuse of alcohol and drugs for the previous 3 months. **MUST submit** urine drug screen for members with history of abuse of drugs other than alcohol. Counseling **MUST** be provided and documented regarding non-abuse of alcohol and drugs as well as education on how to prevent HCV transmission
5. Is the patient receiving dialysis?  Yes  No
6. Is the patient's creatinine clearance  $\geq$ 30 ml/min?  Yes  No
7. Has patient been screened for Hepatitis B?  No  Yes Date: \_\_\_\_\_ Active Disease:  No  Yes If yes, has patient been treated or currently being treated?  No  Yes
8. Patient weight: \_\_\_\_\_ Date obtained: \_\_\_\_\_
9. Does patient have a limited life expectancy (less than 12 months) due to non-liver-related comorbid conditions?  Yes  No

**Prescriber Information:**

10. Provider Practice:  Digestive Disease  Liver Disease  Infectious Disease  Other: \_\_\_\_\_  
If other, note consultation with Specialist:  
Consultation Date: \_\_\_\_\_ Physician Name, Phone & Specialty: \_\_\_\_\_

**Regimens Containing Ribavirin:**

11. If the patient is female and of childbearing potential, or the patient is male with a female partner of childbearing potential, the prescriber must acknowledge the following:
- The patient is not pregnant (or a male patient with a pregnant female partner) and is not planning to become pregnant during treatment or within 6 months of stopping treatment.
  - Both partners will use two forms of effective contraception during treatment and for at least 6 months after stopping treatment.
  - Monthly pregnancy tests will be performed throughout treatment.
12. Complete blood count with differential (**attach results**)
13. If the patient is ineligible for ribavirin<sup>¶</sup>, select the appropriate reason from the list below:
- History of severe or unstable cardiac disease
  - Pregnant women and men with pregnant partners
  - Diagnosis of hemoglobinopathy (e.g., thalassemia major, sickle cell anemia)
  - Hypersensitivity to ribavirin
  - Baseline platelets  $<$ 70,000 cells/ $\mu$ L
  - Baseline absolute neutrophil count  $<$ 1,500 cells/ $\mu$ L
  - Baseline hemoglobin  $<$ 12 g/dL in women or  $<$ 13 g/dL in men
  - Other: \_\_\_\_\_



Iowa Department of Human Services  
**Request for Prior Authorization**  
**HEPATITIS C TREATMENTS**  
(PLEASE PRINT – ACCURACY IS IMPORTANT)

**Note: Laboratory values will be reviewed and requests will not be considered if labs are outside of a specific range. Patients with CrCl <50 ml/min (moderate or severe renal dysfunction, ESRD, HD) should have dosage reduced.**

**Potentially Significant Drug Interactions:**

14. Coadministration of Hepatitis C treatments with the following medications is not recommended. By checking one of the following boxes, the prescriber attests that they have reviewed the patient's medications for potentially significant drug interactions with the Hepatitis C treatment. If the medication list contains one or more of the following medications, the medication(s) will be changed to another agent.

- ledipasvir/sofosbuvir:** The patient's current medication list does NOT include: carbamazepine, phenytoin, phenobarbital, oxcarbazepine, rifabutin, rifampin, rifapentine, St. John's Wort, ritonavir, tipranavir, Stribild, rosuvastatin, H<sub>2</sub>-receptor antagonists above the following daily doses: famotidine 80 mg, ranitidine/nizatidine 600 mg or cimetidine 1600 mg; or proton-pump inhibitors above the following daily doses: esomeprazole 20 mg, lansoprazole or 30 mg, dexlansoprazole 60mg, omeprazole 20 mg, pantoprazole 40 mg, rabeprazole 20 mg
- Sovaldi:** The patient's current medication list does NOT include: carbamazepine, phenytoin, phenobarbital, oxcarbazepine, rifabutin, rifampin, rifapentine, St. John's Wort, or tipranavir/ritonavir
- sofosbuvir/velpatasvir:** The patient's current medication list does NOT include: all meds listed under Sovaldi plus efavirenz, proton pump inhibitors other than omeprazole 20 mg, topotecan or rosuvastatin at doses > 10 mg/day
- Daklinza:** The patient's current medication list does NOT include significant drug interactions or dose is adjusted appropriately. Consult the full prescribing information for potential drug interactions including MANY that require dosage adjustment.
- Zepatier:** The patient's current medication list does NOT include significant drug interactions. Consult the full prescribing information for potential drug interactions.
- Mavyret:** The patient's current medication list does NOT include atazanavir or rifampin, Consult the full prescribing information for other potential "not recommended" drug interactions.
- Vosevi:** Medication list does NOT include rifampin. Consult the full prescribing information for other potential "not recommended" drug interactions.

**Attach lab results and other documentation**

Prescriber signature (Must match prescriber listed above.)	Date of submission
--	--------------------

**IMPORTANT NOTE:** In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Human Services, that the member continues to be eligible for Medicaid.